GLSI
ACHAT TOTAL: 7 300 titres (~97 003,00 $ US)
- Insiders
- Patel Snehal
- Total bought
- $97,003
- Total sold
- —
- Last activity
- 2026-07-29
- Last synced
-
2026-08-03 21:36:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-03
GLSI presents a meaningful event-driven catalyst — an insider cluster buy following back-to-back UK and European regulatory approvals for the FLAMINGO-01 trial — yielding an effective catalyst signal of ~52.5 after…
The first sentence of the analysis written for GLSI on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 1.061 | 2.624 | 23.741 | 51.228 | 70.629 | |
| Quick Ratio | 1.061 | 2.624 | 23.741 | 51.228 | 70.629 | |
| Solvency Ratio | -3.323 | -11.163 | -30.190 | -29.751 | -11.857 | |
| Cash Ratio | 1.061 | 2.624 | 23.741 | 51.228 | 70.629 | |
| Price To Earnings Ratio | -14.692 | -9.281 | -15.246 | -24.918 | -69.514 | |
| Price To Earnings Growth Ratio | -0.808 | -0.123 | -1.163 | -0.335 | -0.521 | |
| Forward Price To Earnings Growth Ratio | -0.808 | -0.123 | -1.163 | -0.335 | -0.521 | |
| Price To Earnings Diluted Ratio | -14.692 | -9.281 | -15.246 | -24.918 | -69.514 | |
| Price To Earnings Diluted Growth Ratio | -0.808 | -0.123 | -1.163 | -0.335 | -0.521 | |
| Price To Book Ratio | 805.086 | 57.676 | 20.172 | 14.855 | 11.737 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -28.685 | -20.113 | -20.863 | -31.660 | -73.384 | |
| Price To Operating Cash Flow Ratio | -28.685 | -20.113 | -20.863 | -31.660 | -73.384 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 17.491 | 1.616 | 1.044 | 1.020 | 1.014 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.702 | -4.659 | -22.006 | -23.583 | -11.142 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -3,304,484.333 | -2,422,181.000 | 0.000 | -2,066,675.667 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -3,304,484.333 | -2,422,181.000 | 0.000 | -2,066,675.667 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -14.372 | -8.159 | -14.421 | -23.374 | -63.002 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 1.061 | ▼-1.563 | ▼-28.796 |
| Quick Ratio | 1.061 | ▼-1.563 | ▼-28.796 |
| Solvency Ratio | -3.323 | ▲7.840 | ▲13.934 |
| Cash Ratio | 1.061 | ▼-1.563 | ▼-28.796 |
| Price To Earnings Ratio | -14.692 | ▼-5.411 | ▲12.038 |
| Price To Earnings Growth Ratio | -0.808 | ▼-0.685 | ▼-0.218 |
| Forward Price To Earnings Growth Ratio | -0.808 | ▼-0.685 | ▼-0.218 |
| Price To Earnings Diluted Ratio | -14.692 | ▼-5.411 | ▲12.038 |
| Price To Earnings Diluted Growth Ratio | -0.808 | ▼-0.685 | ▼-0.218 |
| Price To Book Ratio | 805.087 | ▲747.410 | ▲623.181 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -28.685 | ▼-8.572 | ▲6.256 |
| Price To Operating Cash Flow Ratio | -28.685 | ▼-8.572 | ▲6.256 |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 17.491 | ▲15.875 | ▲13.054 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -1.702 | ▲2.957 | ▲10.916 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Capital Expenditure Coverage Ratio | -3304484.333 | ▼-882303.333 | ▼-1745816.133 |
| Dividend Paid And Capex Coverage Ratio | -3304484.333 | ▼-882303.333 | ▼-1745816.133 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -14.372 | ▼-6.213 | ▲10.293 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $284.4M | $146.2M | $135.2M | $196.3M | $314.9M | |
| Enterprise value | $278.2M | $142.1M | $128.2M | $182.8M | $287.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -28.06x | -19.55x | -19.78x | -29.49x | -67.05x | |
| EV / Free cash flow | -28.06x | -19.55x | -19.78x | -29.49x | -67.05x | |
| EV / EBITDA | -14.37x | -8.16x | -14.42x | -23.37x | -63.00x | |
| Net debt / EBITDA | 0.32x | 0.23x | 0.79x | 1.72x | 5.96x | |
| Current ratio | 1.06x | 2.62x | 23.74x | 51.23x | 70.63x | |
| Income quality | 0.51x | 0.46x | 0.73x | 0.79x | 0.94x | |
| Graham net-net | $0 | $0 | $1 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $353K | $2.5M | $6.7M | $13.2M | $26.8M | |
| Invested capital | $353K | $2.5M | $6.7M | $13.2M | $26.8M | |
| Return on assets | -313.3% | -425.4% | -127.1% | -58.1% | -16.8% | |
| Operating ROA | -378.7% | -318.1% | -91.1% | -39.5% | -16.5% | |
| Return on tangible assets | -313.3% | -425.6% | -127.2% | -58.1% | -16.8% | |
| Return on equity | -5480.5% | -687.2% | -132.7% | -59.2% | -17.0% | |
| Return on invested capital | -5505.9% | -696.0% | -139.2% | -60.8% | -17.1% | |
| Return on capital employed | -5505.9% | -696.0% | -139.2% | -60.8% | -17.1% | |
| Earnings yield | -6.8% | -11.9% | -6.6% | -4.0% | -1.5% | |
| Free cash flow yield | -3.5% | -5.0% | -4.8% | -3.2% | -1.4% | |
| Capex / Op. cash flow | -0.0% | -0.0% | 0.0% | -0.0% | 0.0% | |
| Capex / Depreciation | 0.2% | 0.1% | 0.0% | 0.1% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 1000106d | 118992d | 3585d | 22317d | 22317d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -1000106d | -118992d | -3585d | -22317d | -22317d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+94.6%EV / Sales n/aEV / EBITDA ▼-76.1%EV / Op. cash flow ▼-8.512Earnings yield ▲+0.051
Profitability
Return on equity ▼-47.933Return on assets ▲+1.120Return on invested capital ▼-48.099Return on capital employed ▼-48.099Operating ROA ▼-0.606Income quality ▲+0.052Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+881113.525Operating cycle n/aCash conversion cycle ▼-881113.525Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-1.563Net debt / EBITDA ▲+0.084Working capital ▼-2179040.000Invested capital ▼-2180819.000Intangibles / Total assets -0.000
Change over 5 years
Valuation
Market cap ▼-9.7%EV / Sales n/aEV / EBITDA ▲+77.2%EV / Op. cash flow ▲+38.983Earnings yield ▼-0.054
Profitability
Return on equity ▼-54.635Return on assets ▼-2.965Return on invested capital ▼-54.888Return on capital employed ▼-54.888Operating ROA ▼-3.622Income quality ▼-0.427Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+977789.110Operating cycle n/aCash conversion cycle ▼-977789.110Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-69.568Net debt / EBITDA ▼-5.638Working capital ▼-26465880.000Invested capital ▼-26478495.000Intangibles / Total assets -0.000
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-22 Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom.
- 2026-07-20 Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01.
- 2026-07-16 Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.
- 2026-07-16 Greenwich LifeSciences The Overlooked Need Greenwich LifeSciences is a single-asset biotech focused on GLSI-100, an immunotherapy for HER2-positive breast cancer, currently in Phase 3 trials. GLSI-100 demonstrated a 70-80% reduction in cancer recurrence in Phase 2b, outperforming approved therapies, with no serious adverse events reported. GLSI trades at a ~$279M market cap, below recent M&A comps, despite advanced clinical progress and a large addressable market in HER2/neu-positive breast cancer.
- 2026-07-09 Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe.
- 2026-06-01 Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026 STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026.
- 2026-06-01 Greenwich LifeSciences Provides Update Regarding Form 10-K Filing STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.
- 2026-06-01 Greenwich LifeSciences Provides Update Regarding Form 10-K Filing STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.
- 2026-05-22 Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission.
- 2026-05-22 Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the Company''s common stock, which continues to trade on the Nasdaq Capital Market under the symbol "GLSI."